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The Journal of Immunology
IL-21 Promotes CD4 T Cell Responses by
Phosphatidylinositol 3-Kinase–Dependent Upregulation of
CD86 on B Cells
Kesley Attridge,*,1 Rupert Kenefeck,† Lukasz Wardzinski,*,† Omar S. Qureshi,*
Chun Jing Wang,† Claire Manzotti,* Klaus Okkenhaug,‡ and Lucy S. K. Walker*,†
The cytokine IL-21 is a potent immune modulator with diverse mechanisms of action on multiple cell types. IL-21 is in clinical use to
promote tumor rejection and is an emerging target for neutralization in the setting of autoimmunity. Despite its clinical potential,
the biological actions of IL-21 are not yet fully understood and the full range of effects of this pleiotropic cytokine are still being
uncovered. In this study, we identify a novel role for IL-21 as an inducer of the costimulatory ligand CD86 on B lymphocytes. CD86
provides critical signals through T cell–expressed CD28 that promote T cell activation in response to Ag engagement. Expression
levels of CD86 are tightly regulated in vivo, being actively decreased by regulatory T cells and increased in response to pathogen-
derived signals. In this study, we demonstrate that IL-21 can trigger potent and sustained CD86 upregulation through a STAT3
and PI3K-dependent mechanism. We show that elevated CD86 expression has functional consequences for the magnitude of CD4
T cell responses both in vitro and in vivo. These data pinpoint CD86 upregulation as an additional mechanism by which IL-21 can
elicit immunomodulatory effects. The Journal of Immunology, 2014, 192: 2195–2201.
I
nterleukin-21 is known to influence multiple parameters of
the immune response. The clinical importance of this path-
way was first appreciated nearly a decade ago with the dem-
onstration that IL-21 could augment antitumor immunity (1, 2), and
this has since become an active area of research (3–5). In addition to
augmenting immunity against tumors, IL-21 signaling can directly
induce apoptotic pathways in chronic lymphocytic leukemia (CLL)
B cells (6, 7) and diffuse large B cell lymphoma (8).
The role of IL-21 in T cell–dependent B cell responses has been
extensively documented. IL-21 critically regulates Ab production,
partly in cooperation with IL-4 (9), and it promotes plasma cell
differentiation in both mice (10) and humans (11). The intimate
interaction between follicular helper T (TFH) cells and germinal
center B cells is also shaped by provision of IL-21; TFH cell–
derived IL-21 directly targets germinal center B cells, reinforcing
their fate decision by sustaining bcl6 expression (12, 13).
Alongside effects on B cells, several studies have also reported
that IL-21 promotes T cell activation. Pre-exposure to IL-21 has
been shown to increase the Ag responsiveness of CD8 T cells (14)
and permit triggering by weak TCR agonists (15). CD4 T cell
responses can also be augmented by IL-21, in part due to its abil-
ity to counteract regulatory T cell suppression (16, 17). The mech-
anisms by which IL-21 directly or indirectly promotes T cell
responses are not yet fully defined. In this study we identify
a novel role for IL-21 in upregulating the expression of the co-
stimulatory ligand CD86 on B cells. We show that this requires
activation of the PI3K pathway and is dependent on the PI3K
subunit p110d, a molecule currently being targeted in the setting
of several B cell malignancies (CLL, non-Hodgkin lymphoma)
(18). The increased expression of CD86 on B cells is shown to
have functional consequences for T cell expansion both in vitro
and in vivo. Collectively, these data suggest an additional mech-
anism by which IL-21 may augment adaptive immune responses
and reveal a further level of T cell/B cell interaction directed by
this cytokine.
Materials and Methods
Mice
DO11.10 TCR transgenic and BALB/c mice were purchased from The
Jackson Laboratory. IL-21R2/2 mice were provided by Manfred Kopf
(ETH Zurich) and were bred with DO11.10 TCR transgenic mice to
generate IL-21R2/2 DO11.10 TCR transgenic progeny. p110dD910A mice
were provided by K.O. Mice were housed at the University of Birmingham
Biomedical Services Unit or at the University College London and used
according to Home Office and institutional guidelines.
Flow cytometry
Cells were stained with mAbs against CD25 (PC61.5; eBioscience), CD4
(LT34; eBioscience), CD19 (1D3), CD86 (GL1; eBioscience), CD80 (16-
10A1), pSTAT1 (14/P-STAT1), pSTAT3 (49/P-STAT3), pSTAT5 (clone 47),
and DO11.10 TCR (KJ1.26; eBioscience). All Abs were purchased from
BD Biosciences unless otherwise indicated. For pSTAT staining, cells were
fixed in 4% paraformaldehyde for 10 min and permeabilized with 100%
ice-cold methanol for 30 min. Statistics were performed using an unpaired
two-tailed t test with a 95% confidence interval.
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Short-term splenocyte cultures
BALB/c splenocytes (13 105) were cultured for 15–16 h alone, with IL-21
at 25, 50, 100 or 200 ng/ml (PeproTech), or with 1 mg/ml LPS (Sigma-
Aldrich). For time course experiments, cells were harvested at 2, 4, 6, 8, or
15 h.
Short-term B cell cultures
Magnetic separation (Miltenyi Biotec) was used to purify CD19+ B cells
from BALB/c or p110dD910A spleen. Cells (13 106) were cultured for 16 h
alone or in the presence of 200 ng/ml IL-21 (PeproTech) or 10 ng/ml IL-4
(PeproTech). For STAT3 inhibition experiments cultures were sup-
plemented with 10, 50, or 100 mM S3I-201 (Calbiochem) as indicated. For
PI3K inhibition experiments cultures were supplemented with 10 mM LY-
294002 (Invitrogen) as indicated. For assessment of activated STAT pro-
teins cells were cultured for 2 h alone or in the presence of 200 ng/ml IL-
21 (PeproTech). For experiments to determine the target of IL-21, 2.5 3
104 BALB/c or IL-21R2/2 B cells were cultured with 2.5 3 104 mag-
netically separated (Miltenyi Biotec) CD4+CD252 T cells from BALB/c or
IL-21R2/2 lymph node for 16 h alone or in the presence of 200 ng/ml IL-
21 (PeproTech).
Confocal microscopy
Magnetic separation (Miltenyi Biotec) was used to purify CD19+ B cells
from BALB/c spleen. Cells (1 3 106) were cultured for 6 h alone, with
200 ng/ml IL-21 (Peprotech), with 10 mg/ml cycloheximide (Sigma-Aldrich),
or with both. Cells were stained with mAb against CD86 (GL1; eBioscience)
and imaged using glass bottom culture dishes (MatTek). Imaging was
carried out using a 3100 oil immersion objective.
RT-PCR
Magnetic separation (Miltenyi Biotec) was used to purify CD19+ B cells
from BALB/c spleen. mRNA was isolated at this point or after culture
of 1 3 106 cells for 16 h alone or in the presence of 200 ng/ml IL-21
(PeproTech). Quantitative PCR was performed to assess the expression of
b2-microglobulin (Eurofins MWG Operon) or CD86 (TaqMan gene ex-
pression assay; Applied Biosystems).
In vitro proliferation assays
Magnetic separation (Miltenyi Biotec) was used to purify CD4+CD252
T cells from IL-21R2/2 lymph node. Cells (2.5 3 104) were cultured with
2.53 104 CD19+ B cells from BALB/c or IL-21R2/2 spleen, with 0.8 mg/ml
anti-CD3 (BD Biosciences) alone or in the presence of 10 mg/ml anti-CD86
(Bio X Cell). Triplicate wells were pooled and harvested at day 1 to assess
CD86 expression or day 3 to determine cell counts by flow cytometry.
Adoptive transfers
CD19+ B cells from BALB/c or IL-21R2/2 spleen were isolated by
magnetic separation (Miltenyi Biotec) and cultured for 16 h with 1 mg/ml
OVA peptide. Peptide-pulsed cells (3 3 106) were injected i.v. into IL-
21R2/2 recipients. Magnetic separation (Miltenyi Biotec) was used to
purify CD4+ cells from IL-21R2/2 DO11.10 TCR+ lymph node. Twenty-
four hours after B cell transfer, a total of 2 3 106 CellTrace Violet–labeled
IL-21R2/2 DO11.10 TCR+ T cells were injected i.v. and 1 mg IL-21
(PeproTech) or PBS i.p. Where indicated recipients were also given
100 mg anti-CD86 (Bio X Cell) or PBS i.p. immediately after T cell
transfer. Mice were culled at day 7 for analysis of inguinal lymph node
and splenic cells.
Results
IL-21 upregulates CD86 expression on B cells
To explore the influence of IL-21 on costimulatory ligand ex-
pression, murine splenocytes were cultured in the presence or
absence of IL-21 for 16 h and the expression of CD86 and CD80
was assessed by flow cytometry. We noted a marked elevation of
CD86, but not CD80, on CD19+ B cells in the timeframe examined
(Fig. 1A). Titration (Fig. 1B) and time course (Fig. 1C) data
established that IL-21–mediated CD86 upregulation was dose-
dependent and appeared maximal at ∼8 h following stimulation.
The magnitude of CD86 upregulation observed in response to IL-
21 was comparable, if not greater, than that seen with a 1 mg/ml
dose of LPS, a TLR ligand known to drive CD86 upregulation
(Fig. 1D). In contrast, splenic dendritic cells (DCs) showed some
CD86 expression at baseline and this was not further elevated by
IL-21 under the conditions assessed (Supplemental Fig. 1).
FIGURE 1. IL-21 upregulates CD86 expression on B cells. (A) BALB/c
splenocytes (1 3 105) were cultured for 16 h alone or in the presence of 200
ng/ml IL-21. Plots show representative CD80 and CD86 expression for gated
CD19+ B cells. (B) BALB/c splenocytes (1 3 105) were cultured for 16 h
alone or in the presence of the indicated doses of IL-21. Histograms show
CD86 expression for gated CD19+ B cells and graph shows collated CD86
mean fluorescence intensity (MFI) data. (C) BALB/c splenocytes (1 3 105)
were cultured alone or in the presence of 200 ng/ml IL-21 and harvested at the
indicated time points. Graph shows collated CD86 MFI data for gated CD19+
B cells. (D) BALB/c splenocytes (13 105) were cultured for 16 h alone or in
the presence of either 200 ng/ml IL-21 or 1 mg/ml LPS. Graph shows collated
CD86 MFI data for gated CD19+ B cells. Data are representative of at least
three independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001.
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CD86 upregulation requires direct signaling to B cells and
protein neosynthesis
Because the above assays did not use purified B cells, it re-
mained possible that IL-21 was altering CD86 expression in-
directly by acting on a different cell type. In this regard we have
previously shown that conventional CD4 T cells express high
levels of IL-21R and can respond to IL-21 by acquiring resis-
tance to regulatory T cell suppression (19). To dissect whether
regulation of CD86 expression involved direct signaling to B cells
or was an indirect consequence of IL-21 signaling to T cells,
we took advantage of mice genetically deficient for the IL-21R
(20). Cocultures of T cells and B cells were established in which
the cells derived from either wild-type or IL-21R–deficient mice
and these were incubated for 16 h with or without IL-21. As ex-
pected, when both T and B cells expressed IL-21R, IL-21 up-
regulated CD86 expression (Fig. 2A, far left panels) and when
neither cell type expressed IL-21R, CD86 was unchanged (Fig.
2A, second panels). Crucially, in situations where B cells were
IL-21R+/+ but T cells were IL-21R2/2, addition of IL-21 retained
the capacity to upregulate CD86 (Fig. 2A, third panels). Fur-
thermore, preventing B cells alone from receiving IL-21 signals
completely abrogated the ability of IL-21 to upregulate CD86
(Fig. 2A, far right panels). Collectively, these data indicate that
direct signaling of IL-21 to B cells is responsible for mediating
CD86 upregulation.
The upregulation of CD86 by the cytokine IFN-g has been
reported to be independent of protein neosynthesis (21). To ex-
amine whether upregulation of CD86 by IL-21 required protein
neosynthesis, we performed experiments using purified B cells in
the presence or absence of cycloheximide. The ability of IL-21 to
upregulate B cell CD86 expression was completely abrogated in
the presence of cycloheximide, indicating a requirement for pro-
tein neosynthesis (Fig. 2B, 2C). We next assessed whether up-
regulation of CD86 by IL-21 was transcriptionally regulated; this
revealed that mRNA for CD86 was strongly upregulated by ex-
posure to IL-21 (Fig. 2D). Taken together, these data indicate that
de novo transcription and translation of CD86 mRNA is required
for IL-21–mediated CD86 upregulation.
CD86 upregulation requires STAT3 and PI3K
IL-21 signaling is known to involve STAT3 activation in both
mouse (22) and human (23, 24) B cells, and the ability of STAT3
to mediate IL-21 effects has been demonstrated using B cells
isolated from STAT3-deficient patients (25). We confirmed the
ability of IL-21 to activate the STAT3 pathway in B cells (Fig. 3A)
and then sought to determine whether this pathway was involved
in IL-21–mediated CD86 upregulation. In the presence of the STAT3
inhibitor S3I-201, IL-21 was no longer able to induce significant
CD86 upregulation (Fig. 3B, 3C), suggesting a critical role for
STAT3 in this process.
A second major pathway triggered by IL-21 is the activation of
the enzyme PI3K (22, 26), and the ability of BCR engagement to
upregulate CD86 is known to be dependent on PI3K signaling (27).
To determine whether IL-21 upregulates CD86 via a PI3K-dependent
pathway, we first employed the PI3K inhibitor LY-294002. Strikingly,
IL-21–mediated CD86 upregulation was completely abrogated in the
presence of this inhibitor (Fig. 4A). The related cytokine IL-4
retained the ability to upregulate CD86 in the presence of the PI3K
inhibitor, consistent with previous studies (27). We next took ad-
vantage of mice expressing a catalytically inactive form of the PI3K
p110d subunit (D910A mice) (28), because this subunit is known to
be important in the B cell lineage (29, 30). Purified B cells from
D910A animals failed to upregulate CD86 in response to IL-21,
whereas their ability to upregulate CD86 in response to IL-4
remained intact (Fig. 4B). Collectively, these data indicate that
IL-21 uses STAT3 and PI3K to drive CD86 upregulation and
pinpoint p110d as the critical PI3K subunit responsible.
IL-21–mediated CD86 upregulation has functional
consequences in vitro
To test whether the upregulation of CD86 in response to IL-21 had
functional consequences, in vitro T cell proliferation assays were
performed. CD4+CD252 T cells from IL-21R2/2 mice were used
to preclude direct effects of IL-21 on the T cells themselves. IL-
21R2/2 T cells were activated by anti-CD3 in the presence of
B cells that were either wild-type or IL-21R deficient; in this
setting any IL-21 made by the T cells would potentially be able to
FIGURE 2. Induction of CD86 by IL-21 requires
direct signaling to B cells and is dependent on protein
neosynthesis. (A) BALB/c CD4+CD252 conventional
T cells (2.5 3 104) were cultured with 2.5 3 104
CD19+ B cells for 16 h alone or in the presence of 200
ng/ml IL-21. Cell populations were deficient for the IL-
21R as indicated. Plots show CD86 expression for gated
CD19+ B cells. (B) BALB/c CD19+ B cells (1 3 106)
were cultured for 6 h alone, with 200 ng/ml IL-21, with
10 mg/ml cycloheximide, or both. Representative con-
focal microscopy images show CD86 staining. Scale
bars, 10 mm. (C) Graph shows collated CD86 mean fluo-
rescence intensity (MFI) for cells from (B) analyzed by
flow cytometry. Data are representative of three inde-
pendent experiments. (D) BALB/c CD19+ B cells (1 3
106) were cultured for 16 h alone or in the presence of
200 ng/ml IL-21. Graph shows relative CD86 mRNA
expression for cultured cells and freshly isolated CD19+
B cells. Data are representative of three independent
experiments. **p , 0.01.
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upregulate CD86 on the wild-type B cells but not the IL-21R2/2
ones. In line with this, CD86 was upregulated to a greater extent
on the IL-21R+/+ B cells than on the IL-21R2/2 ones (Fig. 5A). IL-4
did not appear to contribute to CD86 upregulation in this setting as
assessed by inclusion of blocking anti–IL-4 Ab (data not shown).
The increased CD86 expression on IL-21R+/+ B cells was associated
with significantly greater T cell proliferation (Fig. 5B) and activa-
tion marker expression (Fig. 5C and data not shown). T cell pro-
liferation and activation marker expression was dependent on CD86
as demonstrated by Ab blockade of this pathway (Fig. 5B, 5C).
IL-21–mediated CD86 upregulation has functional
consequences in vivo
To extend the above observations to an in vivo setting, we es-
tablished a system in which peptide-pulsed B cells were used to
stimulate the proliferation of Ag-specific CD4 T cells. Wild-type
or IL-21R2/2 B cells were pulsed with OVA323–339 peptide and
adoptively transferred into IL-21R2/2 hosts. OVA-specific T cells
(DO11) that were also IL-21R2/2 were CellTrace labeled and
injected into the same hosts, so that their response to the OVA-
pulsed B cells could be tracked. To maximize the effects of IL-21
on B cell phenotype, rIL-21 was injected i.p. where indicated.
Ensuring that the host animals and the adoptively transferred
T cells were IL-21R2/2 allowed us to restrict the IL-21 effects to
the B cell compartment. At day 7, single-cell suspensions from
inguinal lymph node and spleen were stained by flow cytometry to
identify the adoptively transferred Ag-specific T cells and assess
their proliferation status (Fig. 6A). CellTrace profiles for gated
Ag-specific T cells revealed greater proliferation in mice that had
received IL-21R+/+ B cells compared with those that had received
IL-21R2/2 B cells. Proliferation was particularly evident in the
FIGURE 3. Induction of CD86 by IL-21 is dependent on STAT3 activa-
tion. (A) BALB/c CD19+ B cells (1 3 106) were cultured for 2 h alone or in
the presence of 200 ng/ml IL-21. Histograms show representative staining for
phosphorylated STAT proteins as indicated. (B) BALB/c CD19+ B cells (13
106) were cultured for 16 h alone or in the presence of 200 ng/ml IL-21,
100 mM S3I-201, or both. Histograms show representative CD86 expression
for gated CD19+ B cells. (C) Graph shows collated CD86 expression data for
cells from B when cultured with the indicated doses of S3I-201. Data are
representative of three independent experiments. *p , 0.05, **p , 0.01.
FIGURE 4. Induction of CD86 by IL-21 is dependent on PI3K p110d.
(A) BALB/c CD19+ B cells (13 106) were cultured for 16 h alone or in the
presence of 200 ng/ml IL-21 or 10 ng/ml IL-4. Where indicated, cultures
also contained 10 mM LY-294002. Histograms show CD86 expression for
gated CD19+ B cells. (B) BALB/c CD19+ B cells (1 3 106) were cultured
for 16 h alone or in the presence of 200 ng/ml IL-21 or 10 ng/ml IL-4.
Cells expressed the wild-type or mutant isoforms of PI3K P110d as indi-
cated. Histograms show CD86 expression for gated CD19+ B cells. Data
are representative of three independent experiments.
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spleen, consistent with the likely trafficking of the adoptively
transferred peptide-pulsed B cells to this site. The enhanced T cell
response to IL-21R+/+ B cells was also reflected in higher absolute
numbers of Ag-specific T cells (Fig. 6B). The ability of IL-21
signaling to B cells to augment the T cell response was depen-
dent on CD86 as assessed by in vivo Ab blockade (Fig. 6C).
Recovery of injected B cells at day 1 confirmed increased ex-
pression of CD86 on IL-21R+/+ B cells compared with IL-21R2/2
B cells (Supplemental Fig. 2). Collectively, these data demonstrate
that IL-21 increases expression of CD86 on B cells and that
this increased availability of costimulatory ligand has functional
consequences for the magnitude of T cell responses in vitro and
in vivo.
Discussion
IL-21 is recognized to exert multiple effects on the differentiation
and function of B cells. Although first recognized for its ability to
promote human B cell proliferation (31), it can also trigger B cell
apoptosis (32) with the outcome of IL-21R signaling most likely
dictated by its context (10, 33). IL-21 has a well-established role
in the induction of plasma cell differentiation (10, 11) and this
involves the cooperative binding of STAT3 and IFN regulatory
factor 4 to the IL-21 response element in the Prdm1 gene encoding
Blimp-1 (34). Intriguingly, IL-21 also promotes the expression of Bcl6
a key transcriptional regulator of germinal center B cell differ-
entiation (12, 13), despite the fact that Blimp-1 and Bcl6 have
mutually antagonistic effects. Thus IL-21 acts at multiple stages to
modulate B cell activation, differentiation, and death. Our recent
findings provide additional insight into the effects of IL-21 on
B cells, demonstrating an upregulation of CD86 that has conse-
quences for T cell–dependent immune responses.
The role of IL-21 in DCs is less well studied and our side-by-side
comparison of B cells and DCs suggested CD86 was not obviously
upregulated by IL-21 in the latter population. Whereas it has been
shown that IL-21 can inhibit DC maturation (35, 36), other studies
suggested IL-21 can enhance DC function (37), and recent anal-
ysis has identified a role for IL-21 in triggering DC migration in
a virus-induced diabetes model (38). Interestingly, in the latter
study, reduced migration of IL-21R2/2 DCs was accompanied
by decreased CD86 expression. Thus, further work is required to
fully elucidate the biological function of IL-21 in DCs.
The provision of CD28 costimulation is known to be of critical
importance in thresholding T cell responses. As a consequence,
stimuli that alter expression of the costimulatory ligands CD86 and
CD80 are likely to have a significant impact on T cell immunity.
This is particularly true of CD86, as it is thought to be the dominant
ligand for driving T cell responses (39). Expression of CD86 and
CD80 is tightly regulated, and the CD28 homolog CTLA-4 serves
to limit their availability by competitive inhibition and ligand
downregulation (40–42). Unregulated availability of ligands, in
mice lacking CTLA-4, results in unfettered T cell responses that
culminate in lethal autoimmunity (43, 44). Thus, restricting CD86
and CD80 expression represents a major control point for adaptive
immunity. Counteracting the downregulation of ligand by CTLA-4,
various inflammatory stimuli serve to enhance ligand expression.
Accordingly, TLR ligands and cytokines such as IFN-g have been
shown to upregulate CD86 expression. In this study, we identify IL-
21 as a potent upregulator of CD86 expression on B cells.
IL-21 is one of several cytokines associated with systemic au-
toimmunity (45) and has been linked with lupus pathogenesis in
mice (10, 46) and humans (47). The capacity of IL-21 to upreg-
ulate CD86 and promote T cell costimulation could conceivably
contribute to its pathogenic effects. Consistent with this, B cell
expression of the costimulatory ligands CD86 and CD80 has been
shown to be essential for autoreactive T cell activation and de-
velopment of joint pathology in the proteoglycan-induced arthritis
model in mice (48).
FIGURE 5. IL-21 signaling to B cells promotes CD86-dependent T cell
proliferation. IL-21R2/2 CD4+CD252 conventional T cells (2.5 3 104)
were cultured with 0.8 mg/ml anti-CD3 and 2.5 3 104 IL-21R2/2 or IL-
21R+/+ CD19+ B cells alone or in the presence of 10 mg/ml anti-CD86. (A)
Graph shows collated CD86 mean fluorescence intensity (MFI) data for
gated CD19+ B cells harvested after 16 h in the absence of anti-CD86
blocking Ab. (B) Graph shows collated data for absolute CD4+ conven-
tional T cell counts after harvest at day 3 when cultured with IL-21R2/2 or
IL-21R+/+ B cells as indicated. (C) Graph shows collated CD25 MFI data
for CD4+ conventional T cells from (B). *p , 0.05, **p , 0.01.
FIGURE 6. IL-21 signaling to B cells promotes CD86-dependent T cell
proliferation in vivo. (A) OVA peptide-loaded IL-21R2/2 or IL-21R+/+
CD19+ B cells (3 3 106) were adoptively transferred into IL-21R2/2
recipients. After 24 h, mice received 2 3 106 CellTrace-labeled IL-21R2/2
DO11+ CD4+ T cells i.v. and 1 mg IL-21 i.p. Histograms show representative
CellTrace dilution for gated CD4+DO11+ T cells harvested from spleens or
inguinal lymph nodes of IL-21R2/2 or IL-21R+/+ B cell recipients at day 7.
(B) Graph shows representative absolute CD4+DO11+ T cell counts from (A).
(C) IL-21R2/2 T cells were activated in the presence of OVA peptide loaded
IL-21R2/2 or IL-21R+/+ CD19+ B cells (as above) and recipient mice re-
ceived 100 mg anti-CD86 or isotype control Ab i.p. on day 1. Graphs show
collated absolute CD4+DO11+ T cell counts. Data are representative of at
least two independent experiments. *p , 0.05.
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A major cellular source of IL-21 is the TFH cell subset that
provides crucial help to B cells during the germinal center reaction
(49–51). Interestingly, IL-4 is also produced by TFH cells and is
known to positively regulate the expression of CD86 during pro-
ductive interactions with B cells. Since B cell–derived CD86
provides critical signals for TFH cell maintenance (52), the pro-
duction of IL-21 and IL-4 provides an elegant mechanism for TFH
cells to solicit their own survival signals.
We show that IL-21–dependent CD86 upregulation is strictly
reliant on STAT3 phosphorylation and PI3K, revealing unap-
preciated roles for these pathways in IL-21–mediated B cell
responses. Using B cells expressing a catalytically inactive iso-
form of p110d, we further identify this PI3K subunit as essential
for the promotion of CD86 by IL-21. In contrast, IL-4–driven
CD86 upregulation is independent of PI3K, consistent with pre-
vious studies that instead identified a role for STAT6 (53). The
precise relationship between PI3K and STAT3 in orchestrating
IL-21–dependent CD86 upregulation is unclear, but preliminary
studies suggest that STAT3 activation is independent of the PI3K
pathway (Supplemental Fig. 3). The PI3K pathway is an important
mediator of lymphocyte survival (54), and inhibitors of the p110d
isoform are in clinical use for the treatment of CLL (55). Our data
suggest that PI3K inhibition may have a greater impact on the
nature of the immune response than previously appreciated; in
addition to blocking Ag-dependent proliferation and survival
signals in B cells, abrogating PI3K signaling may also influence
the costimulatory profile of B cells and their ability to drive CD4
T cell responses.
IL-4 and IL-21 exhibit redundancy in their ability to support
germinal center formation, with deficiency in each pathway alone
having only a minor impact (9). Likewise, either IL-4 or IL-21
appears sufficient to support IgG secretion from mouse (56) or
human (57) B cells in vitro with synergistic activity being seen in
the presence of both. Redundant roles for IL-4 and IL-21 in B cell
CD86 upregulation might explain why mice lacking the PI3K
p110d subunit in B cells retained the capacity to form germinal
centers (58), because IL-4–mediated CD86 upregulation would be
predicted to be intact in this setting. Although IL-21 and IL-4 are
frequently coexpressed in germinal center resident TFH cells (59,
60), the observation that Th17 cells can also provide cognate help
to B cells (61, 62) suggests at least one scenario in which IL-21
provision may be uncoupled from that of IL-4.
Similar to IL-21, the cytokine IL-10 is well known as a plasma
cell differentiation factor. Despite their largely overlapping roles in
promoting plasma cell differentiation, these cytokines have notably
distinct effects on CD86 expression, with IL-10 being generally
accepted to downregulate CD86. Intriguingly, the receptors for
these cytokines appear to be subject to differential kinetic regu-
lation during B cell differentiation, with IL-21 playing an earlier
role than IL-10 (63). This might imply a set window during which
CD86 expression is amenable to IL-21–directed upregulation. If
late IL-10 signals downregulate CD86, this could suggest a re-
quirement for appropriate curtailment of T cell costimulatory
signals for optimal T cell/B cell collaboration. In keeping with the
idea of active downregulation (as well as upregulation) of costim-
ulatory ligands, Bcl6 is known to downregulate CD80 in germinal
center B cells (64). The fine tuning of CD86 and CD80 expression in
germinal center B cells and the consequences for TFH cell homeo-
stasis (52, 65) are incompletely understood and represent key areas
for further investigation.
In summary, we have shown that IL-21 upregulates CD86 ex-
pression on B cells in a manner that depends on the PI3K p110d
subunit. This finding is likely to have important implications for
T cell/B cell collaboration within the germinal center, and for
T cell responses in the wider context of antitumor responses and
autoimmunity.
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